Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China

, MT Newswires - 7:28 AM ET 3/21/2025 default

07:28 AM EDT, 03/21/2025 (MT Newswires) -- Hutchmed (China) ( HCM ) said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.

The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating "promising efficacy." Hutchmed ( HCM ) said the ongoing SYMPHONY-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.

Hutchmed ( HCM ) is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.